Evidence map›Paper›PMID 38223899›Full record

ArticleOpen medicine (Warsaw, Poland)2023

Diagnostic and prognostic value of MR-pro ADM, procalcitonin, and copeptin in sepsis.

Basar Cander, Emin Fatih Visneci, Osman Karaoglan, Fatma Cakmak, Alpay Tuncar, Bahadir Taslidere

Open access · goldAbstract read
In one paragraph

Article in Open medicine (Warsaw, Poland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Basar CanderDepartment of Emergency Medicine, Bezmialem Vakif University, Istanbul, Turkey.
Emin Fatih VisneciDepartment of Emergency Medicine, Konya City Hospital, Konya, Türkiye.
Osman KaraoglanDepartment of Emergency Medicine, Konya Numune Hospital, Konya, Turkey.
Fatma CakmakDepartment of Emergency Medicine, Erzurum City Hospital, Erzurum, Türkiye.
Alpay TuncarDepartment of Emergency Medicine, Konya City Hospital, Konya, Türkiye.
Bahadir TaslidereDepartment of Emergency Medicine, Bezmialem Vakif University, Istanbul, Turkey.
Bezmiâlem Vakıf Üniversitesi · TRKonya Eğitim ve Araştırma Hastanesi · TRErzurum Regional Training and Research Hospital · TRKonya Numune Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. There is a need for biomarkers that can be used for the diagnosis of sepsis and the early identification of patients at high risk of death. In this study, we aimed to investigate the relationship between Mid-regional pro-adrenomedullin (MR-proADM), procalcitonin (PCT), and copeptin in sepsis. A total of 28 sepsis, 32 septic shock, and 30 control patients were included in our prospective study. Patients' MR-proADM, PCT, and copeptin levels were recorded. Sequential organ failure assessment scores, length of hospital stay, and 30-day mortality were also recorded. These values were compared between the sepsis, septic shock, and control groups. The mean age of all participants was 64.04 ± 15.83 years. In the study, 37 (61.6%) patients were female and 23 (39.3%) were male. There was no statistically significant difference in gender/age between all patient groups and the control group (for all,

Indexed as

copeptinMR-proADMprocalcitoninsepsis

Identifiers

PMID38223899
PMCPMC10787304
OpenAlexW4390713832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.